GlassScriptPhysician profile
Megan B Green
NPI 1548592355
$4,912.31
in general payments reported to CMS, 2019-2025
41 companies · $799 in 2025
The $799 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $962 · 2022: $1,317 · 2023: $1,014 · 2024: $821 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $14.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.57 |
| Education | $14.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,165.65 | 2021-2025 | |
| Lilly USA, LLC | $685.71 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $308.43 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $230.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.73 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $172.21 | 2021-2025 | |
| Mylan Specialty L.P. | $171.84 | 2022-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $156.28 | 2022-2025 | Rexulti, Nuedexta |
| Harmony Biosciences LLC | $147.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.51 | 2022 | |
| Astellas Pharma US INC | $107.02 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $105.84 | 2021-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceuticals, INC. | $94.06 | 2021 | |
| Exact Sciences Corporation | $94.00 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.83 | 2021-2024 | Spiriva Respimat |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.